Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
NeyroblastGX LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution is handled by 1 distinct examiner and is situated within 1 distinct art unit. This indicates a highly localized prosecution effort, where all current patent office feedback is originating from a single source and technical division.
The busiest examiner for the portfolio is HOLTZMAN, KATHERINE ANN, who is responsible for 1 busiest examiner pending action. This 1 busiest examiner pending action represents the total 1 pending office action for the company. Because the company is only active in 1 distinct art unit, the prosecution strategy is heavily influenced by the specific practices of that unit. For practitioners, this means the company's current patent trajectory is defined by the interactions with Katherine Ann Holtzman in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLTZMAN, KATHERINE ANN | 1 | 65.7% | +58.3% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324091 | FULLY FUNCTIONAL CONTRACTILE GASTROINTESTINAL ORGANOID SYSTEM, GENERATED FROM HUMAN-INDUCED PLURIPOTENT STEM CELLS TO DEVELOP A HIGH THROUGHPUT SYSTEM FOR DETECTING EXISTING AND NEWLY-EMERGING PATHOGENS, DRUGS, TOXICITY AND THEREOF | KASAYAN, KATRIEL BARCELLANO | 8d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324105 | GENETICALLY ENGINEERED DENDRITIC CELLS TO ACTIVATE PROTEIN SPECIFIC T CELLS FOR THE TREATMENT OF VIRAL AND OTHER PATHOGENIC INFECTIONS | HOLTZMAN, KATHERINE ANN | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18324105 | GENETICALLY ENGINEERED DENDRITIC CELLS TO ACTIVATE PROTEIN SPECIFIC T CELLS FOR THE TREATMENT OF VIRAL AND OTHER PATHOGENIC INFECTIONS | HOLTZMAN, KATHERINE ANN | 1646 | §103 | Final Rejection | 49d overdue | Pending | May 25, 2023 |
| 18324091 | FULLY FUNCTIONAL CONTRACTILE GASTROINTESTINAL ORGANOID SYSTEM, GENERATED FROM HUMAN-INDUCED PLURIPOTENT STEM CELLS TO DEVELOP A HIGH THROUGHPUT SYSTEM FOR DETECTING EXISTING AND NEWLY-EMERGING PATHOGENS, DRUGS, TOXICITY AND THEREOF | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112 | Final Rejection | 8d overdue | Pending | May 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial